NCT02574130View on ClinicalTrials.gov

Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Pneumonia, Ventilator-Associated
Interventions
DRUG

Amikacin

400 mg, nebulizer, every 12 hours, 10 days

DRUG

Placebo

placebo 4 ml, nebulizer, every 12 hours, 10 days

Trial Locations (1)

12120

Thammasat University (Rangsit center), Pathum Thani

All Listed Sponsors
lead

Thammasat University

OTHER

NCT02574130 - Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria | Biotech Hunter | Biotech Hunter